- Home
- INBX vs CGEM Comparison
INBX vs CGEM Comparison
Compare INBX & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- CGEM
- Stock Information
- Founded
- INBX 2010
- CGEM 2016
- Country
- INBX United States
- CGEM United States
- Employees
- INBX N/A
- CGEM N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- CGEM Health Care
- Exchange
- INBX Nasdaq
- CGEM Nasdaq
- Market Cap
- INBX 430.2M
- CGEM 437.2M
- IPO Year
- INBX 2020
- CGEM 2021
- Fundamental
- Price
- INBX $83.93
- CGEM $9.77
- Analyst Decision
- INBX Hold
- CGEM Strong Buy
- Analyst Count
- INBX 2
- CGEM 7
- Target Price
- INBX N/A
- CGEM $26.29
- AVG Volume (30 Days)
- INBX 458.6K
- CGEM 881.9K
- Earning Date
- INBX 11-14-2025
- CGEM 11-06-2025
- Dividend Yield
- INBX N/A
- CGEM N/A
- EPS Growth
- INBX N/A
- CGEM N/A
- EPS
- INBX N/A
- CGEM N/A
- Revenue
- INBX $1,400,000.00
- CGEM N/A
- Revenue This Year
- INBX $563.00
- CGEM N/A
- Revenue Next Year
- INBX $230.77
- CGEM N/A
- P/E Ratio
- INBX N/A
- CGEM N/A
- Revenue Growth
- INBX N/A
- CGEM N/A
- 52 Week Low
- INBX $10.81
- CGEM $5.68
- 52 Week High
- INBX $86.64
- CGEM $13.78
- Technical
- Relative Strength Index (RSI)
- INBX 71.64
- CGEM 71.84
- Support Level
- INBX $79.05
- CGEM $8.52
- Resistance Level
- INBX $85.75
- CGEM $9.10
- Average True Range (ATR)
- INBX 6.92
- CGEM 0.71
- MACD
- INBX -0.97
- CGEM 0.19
- Stochastic Oscillator
- INBX 81.14
- CGEM 95.75
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.